Omalizumab: A future innovation for treatment of severe ocular allergy?

Expert Opinion on Biological Therapy

Volumn 5, Issue 12, 2005, Pages 1603-1609

  Williams, Patricia B ^a   Sheppard Jr , John D ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Allergy; Conjunctivitis; Monoclonal IgE antibody; Omalizumab

Indexed keywords

ACETAZOLAMIDE; ANTIHISTAMINIC AGENT; BECLOMETASONE; CYCLOSPORIN A; DEXAMETHASONE; FC RECEPTOR; IMMUNOGLOBULIN E; KETONE DERIVATIVE; LOTEPREDNOL ETABONATE; METHOTREXATE; OMALIZUMAB; PREDNISOLONE ACETATE; PREDNISONE; RIMEXOLONE; STEROID;

ALLERGIC ASTHMA; ALLERGIC REACTION; APLASTIC ANEMIA; ATOPIC DERMATITIS; ATOPIC KERATOCONJUNCTIVITIS; CATARACT; CATARACTOGENESIS; CLINICAL TRIAL; CONTACT DERMATITIS; DIABETES MELLITUS; DRUG EFFECT; DYSGEUSIA; GLAUCOMA; HEADACHE; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPOTHESIS; IMMUNOCOMPETENT CELL; INFECTION; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; METABOLIC ACIDOSIS; NEPHROLITHIASIS; PHARYNGITIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOSIS; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS KERATITIS; VIRUS REPLICATION;

AGED; ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; CONJUNCTIVITIS, ALLERGIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; KERATOCONJUNCTIVITIS; MALE;

EID: 28844497377     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.12.1603     Document Type: Review

References (20)

1. ONO SJ, ABELSON MB: Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. (2005) 115(1):118-122.
2. FRIEDLAENDER MH: The current and future therapy of allergic conjunctivitis. Curr. Opin. Ophthalmol. (1998) 9:54-58.
3. BIELORY L: Ocular allergy guidelines: a practical treatment algorithm. Drugs (2002) 62(11):1611-1634.
4. STAHL JL, BARNEY NP: Ocular allergic disease. Curr. Opin. Allergy Clin. Immunol. (2004) 4(5):455-459.
5. ZHAN H, SMITH L, CALDER V, BUCKLEY R, LIGHTMAN S: Clinical and immunological features of atopic keratoconjunctivitis. Int. Ophthalmol. Clin. (2003) 43(1):59-71.
6. OUSLER GW, WILCOX KA, GUPTA G, ABELSON MB: An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann. Allergy Asthma Immunol. (2004) 93(5):460-464.
7. SAMUDRE SS, LATTANZIO FRANK JR, WILLIAMS PB, SHEPPARD JD JR: Comparison of topical steroids for acute anterior uveitis. J. Ocul. Pharmacol. Ther. (2004) 20(6):533-547.
8. AKPEK EK, DART JK, WATSON S et al.: A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology (2004) 111:476-482.
9. ROMANOWSKI EG, PLESS P, YATES KA, GORDON YJ: Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea (2005) 24:86-91.
10. RIKKERS SM, HOLLAND GN, DRAYTON GE, MICHEL FK, TORRES MF, TAKAHASHI S: Topical tacrolimus treatment of atopic eyelid disease. Am. J. Ophthalmol. (2003) 135(3):297-302.
11. JOSEPH MA, KAUFMAN HE, INSLER M: Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea (2005) 24:417-420.
12. KATELARIS CH: Ocular allergy: implications for the clinical immunologist. Ann. Allergy Asthma Immunol. (2003) 6(3):23-27.
13. OETTGEN HC, GEHA RS: IgE in asthma and atopy: cellular and molecular connections. J. Clin. Invest. (1999) 104:829-835.
14. BACON AS, AHULUWALIA P, IRANI AM et al.: Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol. (2000) 106:948-954.
15. BUHL R: Anti-IgE antibodies for the treatment of asthma. Curr. Opin. Pulm. Med. (2004) 11:27-34.
16. BERGER W, GUPTA N, MCALARY M, FOWLER-TAYLOR A: Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann. Allergy Asthma Immunol. (2003) 91:182-188.
17. NO AUTHORS LISTED: Xolair. In: Physicians Desk Reference. Duplay D (Ed.), Thompson PDR, Montvale, NJ, USA (2005): 1359-1362.
18. SCHIFFMAN RM, CHRISTIANSON MD, JACOBSEN G, HIRSCH JD, REIS BL: Reliability and validity of the ocular surface disease index. Arch. Ophthalmol. (2000) 118:615-621.
19. WILLIAMS PB, MCDONALD KW, SHEPPARD JD JR, LATTANZIO FA JR: Omalizumab for severe ocular allergy. J. Clin. Pharmacol. (2004) 44:1200.
20. WILLIAMS PB, SIMON DJ, SHEPPARD JD JR, LATTANZIO FA JR: Omalizumab improves symptoms of severe ocular allergy. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, USA (2005) (also available from www.arvo.org).